10 CEOs Transforming Healthcare In America forbes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forbes.com Daily Mail and Mail on Sunday newspapers.
49% of patients treated with Opdivo plus Yervoy were alive at 6.5 years and 77% of these patients remained treatment-free Data to be featured in an oral presentation during the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting Bristol Myers Squibb (NYSE: BMY) today announced new six-and-a-half-year data from CheckMate -067, a randomized, double-blind, Phase 3 clinical trial, demonstrating durable improvement in survival with first-line Opdivo (nivolumab) plus Opdivo monotherapy, versus Yervoy alone, in patients with advanced melanoma. With a minimum follow-up of 6.5 years, median overall survival (OS) was 72.1 months with Opdivo plus Yervoy (95% CI: 38.2-NR), the longest reported median OS in a Phase 3 advanced melanoma trial, 36.9 months with
Responses observed across a broad range of antigen expression -
Initial safety and durability are encouraging -
PHILADELPHIA, PA., and OXFORDSHIRE, U.K., May 20, 2021 Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report initial data from its Phase 2 SPEARHEAD-1 trial, with afamitresgene autoleucel (afami-cel, formerly ADP-A2M4), at the American Society of Clinical Oncology (ASCO) congress. Full abstracts were released online today. Data will be presented in an oral presentation by Dr. Sandra D Angelo of the Memorial Sloan Kettering Cancer Center (Abstract #11504) on June 4th. Patients are seeing substantial benefit from afami-cel in SPEARHEAD-1 across a broad range of cell doses and levels of MAGE-A4 expression, said Adrian Rawcliffe, Adaptimmune Chief Executive Officer. We have shown a high response rate and these responses are still evolving in many patients with increasing depths of response over time and encouraging durability
Share this article
Share this article
SEATTLE, May 19, 2021 /PRNewswire/ OnQuality Pharmaceuticals ( OnQuality ), a targeted cancer supportive care company developing medications to address specific side effects and improve the quality of life for patients receiving anti-cancer medications, today announced that abstracts for the NOVA-II clinical trial evaluating OnQuality s lead candidate, OQL011, have been selected for presentations at two upcoming meetings: a Trial in Progress poster presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, being held virtually from June 4-8, 2021, and an oral presentation at the Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASCC/ISOO) Annual Meeting, being held virtually from June 24-26, 2021. The abstracts for both presentations include an update on the ongoing Phase II clinical trial and are both titled A Study to Investigate OQL011 on VEGFR Inhibitor-Associated
no
ocular findings and an overall safety profile in line with what we saw in the monotherapy setting. It’s
notable
to see this kind of activity in patients with ER+ metastatic breast cancer, where there is a clear need for new therapeutic options.”
In this preliminary analysis from the open-label AMEERA-1 study, amcenestrant was evaluated in dose escalation cohorts (Part C) at 200mg (n=9) and 400mg (n=6) daily and in a dose expansion cohort (Part D; n=30) at 200mg daily, all in combination with a standard dose of palbociclib. Eligible patients included post-menopausal women with ER+/HER2- MBC who were pre-treated with endocrine therapy in the advanced setting for at least six months or had resistance to adjuvant endocrine therapy.